 Health Canada has approved to test Edesa Biotech Incs NASDAQ: EDSA monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a Phase 23 clinical study. Approval of the companys Phase 3 study design follows favorable Phase 2 results, demonstrating preliminary evidence of EB05s ability to reduce mortality in the sickest patients. 